JAMMU, Mar 13: The Department of Surgical Oncology at All India Institute of Medical Sciences (AIIMS) Jammu has successfully performed a highly complex surgery on a patient with a large left adrenal ...
Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent ...
Blood pressure is the force created when blood moves through the blood vessels in the body. Every time the heart beats, it pushes blood through the arteries, and this pressure helps deliver oxygen and ...
2don MSN
Sonodynamic therapy is safe and well-tolerated in high-grade gliomas, first-in-human trial suggests
High-grade gliomas, especially glioblastoma (GBM) and others, remain among the most aggressive brain cancers, with few ...
The incidence of adrenocortical carcinoma is stable over time, but the survival for stage IV disease has improved, with the centralisation of care being associated with better survival.
Although the Graves disease treatment landscape remains challenging, emerging therapies could shift existing treatment ...
The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates (ADCs), a class of treatments that are designed to deliver potent che ...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...
Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancements in diagnosis and prognosis, and personalized treatment for renal cell carcinoma (RCC) session and a presentation ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results